Mucoepidermoid carcinoma of the breast is a very rare type of neoplasm with a very distinct histology, immunohistochemistry as well as prognostic characteristics. Two cases of this type of breast carcinoma are presented. Both tumors were microscopically composed of intermediate, epidermoid and glandular cells. The first case was a high grade tumor with focal necroses, where epidermoid and mucinous cells were found only as isolated elements. The second case was of low grade, the squamous cells showed keratinization and glandular cells formed distinct small lumina. The prognostic characteristics, differential diagnosis, grading system and immunohistochemical profile of these rare neoplasms are described.
"MEC of the breast is a rare entity with an estimated incidence of 0.2% and is composed of a mixture of basaloid, intermediate, epidermoid, and mucinous cells (Camelo-Piragua et al., 2009; Fisher et al., 1983). Since Patchefsky et al. first described breast MEC in 1979, only 28 cases have been reported (Berry et al., 1998; Chang et al., 1998; Di Tommaso et al., 2004; Fisher et al., 1983; Gomez-Aracil et al., 2006; Hanna et al., 1985; Hastrup et al., 1985; Hornychova et al., 2007; Kovi et al., 1981; Leong et al., 1985; Luchtrath et al., 1989; Markopoulos et al., 1998; Patchefsky et al., 1979; Pettinato et al., 1989; Ratanarapee et al., 1983; Tjalma et al., 2002). Because of its rarity, the prognosis remains controversial debatable matter. "
[Show abstract][Hide abstract] ABSTRACT: Background: Mucoepidermoid carcinoma (MEC), which is primarily found in the salivary glands, is rarely seen in the breast. These tumors usually develop from squamous and mucus-secreting cells. Histological grading is an important prognostic factor. Case Report: We present herein a case of a 69-year-old female patient with a painful mass in the left breast. Of importance is that, in addition to MEC, the patient had a wide area of scar tissue secondary to a burn that completely occupied the left bottom quadrant of the abdomen and retracted the left nipple up to the left upper quadrant. Fine needle aspiration biopsy was negative, and a lumpectomy was performed. Because the pathology results were consistent with MEC, modified radical mastectomy with subsequent adjuvant chemotherapy and radiotherapy was performed. The patient remained disease-free for 12 months after the treatment. In addition to a discussion of this case, we performed a review of the clinicopathological characteristics of 30 cases with breast MEC reported in the English language literature between 1979 and 2010. Conclusions: MEC of the breast is a rarely seen tumor, and this is the first report of MEC in a breast affected by burn scars.
Breast Care 01/2011; 6(4):293-297. DOI:10.1159/000331316 · 0.63 Impact Factor
[Show abstract][Hide abstract] ABSTRACT: Malignant salivary gland tumors (MSGTs) account for 2-6% of all head and neck cancers. Despite the rarity, MSGTs have been of great interest due to a wide variety of pathological features and high metastasis rates resulting in poor prognosis. Surgical resection followed by radiation therapy represents the main treatment of this malignancy. Adjuvant therapy is reserved for the management of local recurrence, no longer amenable to additional local therapy, and for metastasis. Based on the studies from other types of tumors, particularly breast cancer, the expression and function of sex steroid hormone receptors in cancer have been extensively studied and applied to diagnosis and treatment. Although a number of studies in MSGTs have been published, the rationale for hormone therapy is still controversial due to the disparate results and insufficient number of cases. However, some recent reports have demonstrated that certain salivary gland neoplasms are similar to breast cancer, not only in terms of the pathological features, but also at the molecular level. Here, we shed light on the biological similarity between MSGTs and certain types of breast cancer, and describe the potential use of hormone and additional therapies for MSGTs.
International Journal of Otolaryngology 11/2011; 2011(1687-9201):187623. DOI:10.1155/2011/187623
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.